retatrutide triple agonist gip glp-1 glucagon receptor Eli Lilly just announced striking Phase 3 results for retatrutide, an experimental “triple agonist” that acts on three gut-hormone targets at once. On the top dose, people lost an average of 28% #retatrutide is a novel triple

The paper was co-authored by Professor Linong Ji (Peking University Peoples Hospital) and Dr

The IATA released its latest financial outlook for the airline industry over the weekend, forecasting a $98 billion jump in the sectors collective fuel bill

One difference worth noting: short-acting drugs like exenatide maintain their stomach-slowing effects over time, while long-acting drugs like semaglutide tend to show reduced effects after about two weeks , as the body adapts to continuous receptor stimulation

Los agonistas del GLP-1 imitan la accin del GLP-1, una hormona intestinal que estimula la secrecin de insulina dependiente de glucosa, regulando la glucemia

T., Shah M

Its low side-effect profile is also reassuring, making it attractive to those looking for alternative healing options